Evidence map›Paper›PMID 36765668›Full record

ReviewCancers2023

Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.

Toan D Nguyen, Brandon M Bordeau, Joseph P Balthasar

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 232 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
232citing papers in PubMed, 10 pooled it
74.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

232 citing papers in PubMed, 10 syntheses or guidelines pooled it, 325 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Review
  13. Article
  14. A modular framework for antibody-drug conjugate biomarkers.Nature reviews. Clinical oncology · 2026
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

172 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Toan D NguyenDepartment of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14214, USA.
Brandon M BordeauDepartment of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14214, USA.
Joseph P BalthasarDepartment of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14214, USA.ORCID 0000-0001-6340-9370
University at Buffalo, State University of New York · US

Funding

Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimizationR01CA256928 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI BALTHASAR, JOSEPH P · 2021 to 2025
$1.8M
Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumorsR01CA246785 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI BALTHASAR, JOSEPH P, SHAH, DHAVAL K · 2020 to 2024
$1.8M
NCI NIH HHS CA246785, CA256928NCI NIH HHS R01 CA246785NCI NIH HHS R01 CA256928
6 · The paper itself

Abstract

Anti-cancer antibody-drug conjugates (ADCs) aim to expand the therapeutic index of traditional chemotherapy by employing the targeting specificity of monoclonal antibodies (mAbs) to increase the efficiency of the delivery of potent cytotoxic agents to malignant cells. In the past three years, the number of ADCs approved by the Food and Drug Administration (FDA) has tripled. Although several ADCs have demonstrated sufficient efficacy and safety to warrant FDA approval, the clinical use of all ADCs leads to substantial toxicity in treated patients, and many ADCs have failed during clinical development due to their unacceptable toxicity profiles. Analysis of the clinical data has demonstrated that dose-limiting toxicities (DLTs) are often shared by different ADCs that deliver the same cytotoxic payload, independent of the antigen that is targeted and/or the type of cancer that is treated. DLTs are commonly associated with cells and tissues that do not express the targeted antigen (i.e., off-target toxicity), and often limit ADC dosage to levels below those required for optimal anti-cancer effects. In this manuscript, we review the fundamental mechanisms contributing to ADC toxicity, we summarize common ADC treatment-related adverse events, and we discuss several approaches to mitigating ADC toxicity.

Indexed as

ADC toxicity and tolerabilityantibody-drug conjugatecancertargeted therapy

Identifiers

PMID36765668
PMCPMC9913659
OpenAlexW4317932204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.